Table 2 IRs of hospitalisation for VTE per 1000 person-years in the cancer cohort

From: Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006

Characteristic

IR (95% CI)

aRR (95% CI)

Overall

8.0 (7.6–8.5)

4.7 (4.3–5.1)

Sex

 Female

7.0 (6.5–7.7)

4.8 (4.2–5.4)

 Male

9.4 (8.6–10.3)

4.6 (4.1–5.3)

Age, years

 <50

4.3 (3.6–5.2)

8.7 (6.2–12.2)

 50–59

7.9 (6.9–9.0)

9.6 (7.6–12.2)

 60–69

9.6 (8.6–10.7)

5.6 (4.7–6.6)

 70–79

8.9 (7.9–10.0)

3.1 (2.7–3.7)

 80–89

9.5 (8.0–11.4)

2.9 (2.3–3.7)

 90+

8.6 (4.2–17.1)

3.0 (1.1–8.7)

Cancer site

 Oesophagus

16.1 (9.5–27.1)

11.6 (3.8–35.0)

 Stomach

12.7 (8.0–20.2)

8.9 (3.8–20.7)

 Colon

9.5 (8.0–11.3)

4.8 (3.7–6.2)

 Rectum

7.5 (5.7–9.7)

4.0 (2.8–5.9)

 Liver

20.4 (9.2–45.3)

—a

 Pancreas

40.9 (29.5–56.7)

16.3 (8.1–32.6)

 Lung

16.1 (13.6–19.2)

8.0 (6.0–10.7)

 Breast

3.9 (3.3–4.7)

3.3 (2.6–4.2)

 Cervix

4.6 (2.8–7.5)

10.8 (4.2–28.1)

 Endometrium

4.4 (2.9–6.6)

2.2 (1.1–3.9)

 Ovary

12.1 (9.1–15.9)

10.1 (6.1–16.7)

 Prostate

10.0 (8.2–12.2)

3.1 (2.4–4.1)

 Kidney

4.0 (2.3–7.1)

2.7 (1.1–6.6)

 Urinary bladder

10.4 (8.1–13.3)

4.5 (3.1–6.4)

 Brain

17.7 (11.3–27.8)

19.8 (7.1–55.2)

 Hodgkin Lymphoma

5.3 (2.4–11.7)

9.7 (2.3–41.3)

 Non-Hodgkin Lymphoma

9.8 (7.4–13.1)

6.6 (4.2–10.5)

 Leukaemia

13.9 (10.3–18.9)

9.1 (5.3–15.8)

 Multiple Myeloma

22.6 (15.4–33.22)

46.1 (13.1–162.0)

 Bone

7.4 (2.8–19.7)

9.7 (0.7–130.9)

  1. Abbreviations: aRR=adjusted relative risk; CI=confidence interval; IR=incidence rate; VTE=venous thromboembolism.
  2. Cox proportional hazards regression models computing the adjusted relative risks (aRRs) (Adjusted for myocardial infarction, congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, inflammatory bowel disease, peptic ulcer disease, liver disease, renal disease, diabetes, obesity, acute pancreatitis, alcoholism and hypertension when the number of VTE events for a given comorbidity was sufficient) of hospitalisation for VTE in the cancer cohort compared with the general-population (Danish National Registry of Patients, 1997–2005). Please see Supplementary Information for IR and RR by time since diagnosis/index date.
  3. aToo few VTE events to estimate incidence.
Back to article page